BioPharmSignal logoBioPharmSignal

Biotech News

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics (CRSP)CRISPR TherapeuticsConference / presentation

ZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. Jefferies Global Healthcare Conference Date: Wednesday, June 3,

Related news

CRSPCRISPR Therapeutics2026-05-06 12:30 EST

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

CRSPCRISPR Therapeutics2026-04-07 12:00 EST

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

SANASana Biotechnology2026-05-27 20:05 EST

Sana Biotechnology to Present at June 2026 Investor Conferences

CRBUCaribou2026-05-13 20:05 EST

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

CRBUCaribou2026-06-29 12:00 EST

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

SRPTSarepta Therapeutics2026-05-13 20:30 EST

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

EDITEditas Medicine2026-05-28 20:01 EST

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

SRPTSarepta Therapeutics2026-06-01 20:30 EST

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

SANASana Biotechnology2026-05-12 20:05 EST

Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs

NTLAIntellia2026-05-05 11:30 EST

Intellia Therapeutics to Participate in Upcoming Investor Conferences

View all latest news

CRISPR Therapeutics

Gene-Based Medicine Platform CRISPR Therapeutics develops gene-edited medicines across hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare disease. Its toolkit includes CRISPR/Cas9, the SyNTase editing platform, lipid-nanoparticle delivery and engineered cell therapies. CASGEVY CASGEVY...

Recent company news

CRSPCRISPR Therapeutics2026-08-03 20:15 EST

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

CRSPCRISPR Therapeutics2026-05-28 12:00 EST

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRSPCRISPR Therapeutics2026-05-06 12:30 EST

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

CRSPCRISPR Therapeutics2026-05-04 20:30 EST

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

CRSPCRISPR Therapeutics2026-04-07 12:00 EST

CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Stock data

Close
51.64 USD
Market cap
5.02B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States